Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
31.14
-1.03 (-3.20%)
May 13, 2025, 4:00 PM - Market closed
Kymera Therapeutics Revenue
Kymera Therapeutics had revenue of $22.10M in the quarter ending March 31, 2025, with 114.83% growth. This brings the company's revenue in the last twelve months to $58.89M, down -25.85% year-over-year. In the year 2024, Kymera Therapeutics had annual revenue of $47.07M, down -40.11%.
Revenue (ttm)
$58.89M
Revenue Growth
-25.85%
P/S Ratio
40.92
Revenue / Employee
$313,218
Employees
188
Market Cap
2.03B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
KYMR News
- 4 days ago - Kymera Therapeutics, Inc. (KYMR) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 5 days ago - Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases - GlobeNewsWire
- 5 days ago - Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update - GlobeNewsWire
- 7 days ago - Kymera Therapeutics to Participate in Fireside Chat at the BofA Securities 2025 Health Care Conference - GlobeNewsWire
- 22 days ago - Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader - GlobeNewsWire
- 5 weeks ago - Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer - GlobeNewsWire
- 2 months ago - Kymera Therapeutics, Inc. (KYMR) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Kymera Therapeutics to Participate in Upcoming March Investor Conferences - GlobeNewsWire